Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, To Pierre Fabre Laboratories For A Total Consideration Of Up To $31M
Portfolio Pulse from Benzinga Newsdesk
Kinnate Biopharma Inc. has sold its investigational pan-RAF inhibitor, exarafenib, and other assets to Pierre Fabre Laboratories for up to $31M. This sale is part of Kinnate's strategic alternatives exploration. Pierre Fabre will assume all ongoing program costs, with Kinnate receiving $500,000 at closing and up to $30.5M contingent on future milestones. The deal aims to expand the global reach of targeted therapies for solid tumors.

March 01, 2024 | 1:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Kinnate Biopharma Inc. sells its investigational pan-RAF inhibitor, exarafenib, to Pierre Fabre Laboratories for up to $31M, aiming to expand the global reach of targeted therapies for solid tumors.
The sale of exarafenib and other assets to Pierre Fabre Laboratories for up to $31M is a significant strategic move for Kinnate Biopharma Inc. This deal not only provides immediate financial benefits with a $500,000 closing payment but also potential future earnings of up to $30.5M based on achieving certain milestones. This influx of capital and the offloading of ongoing program costs could positively impact Kinnate's financial health and allow it to focus on other strategic initiatives. The deal also highlights Kinnate's commitment to expanding the global reach of targeted therapies for solid tumors, potentially enhancing its reputation in the precision oncology field.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100